<DOC>
	<DOCNO>NCT00834847</DOCNO>
	<brief_summary>The objective study compare relative bioavailability pravastatin 40 mg tablet Pravachol 40 mg tablet healthy adult male subject non-fasting condition . A second objective compare difference plasma level dose test formulation without food .</brief_summary>
	<brief_title>Pravastatin Sodium 40 mg Tablets Food Challenge Study</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Inclusion Criteria Noninstitutionalized subject consist university student member community large . All subject select study male 18 45 ( inclusive ) year age . Weight subject shall 15 % normal height body frame ( Metropolitan Life , 1993 , Height , Weight , Body Chart ) . Each subject shall give general physical examination within 21 day initiation study . Such examination include , limited , blood pressure , general observation , history . At end study subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 21 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) Clinical Chemistry : creatinine , BUN , glucose , SGOT , SGPT , bilirubin , alkaline phosphatase Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell HIV Screen : ( prestudy ) HepatitisB , C Screen : ( prestudy ) Drugs Abuse Screen : ( prestudy dose period checkin ) Subjects select normal . Electrocardiograms participate subject record initiation study file subject 's case report form . Exclusion Criteria Subjects history chronic alcohol consumption , drug addiction , serious gastrointestinal , renal , hepatic , cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . Subjects use tobacco form eligible participate study . Three month abstinence require . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure dose period checkin . Subjects found urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Subjects expose know hepatic enzyme induce inhibit agent within ( 30 ) day prior dose allow participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>